KLRK1 and hepatocellular carcinoma: Combining NKG2D CAR-T cells with NKG2DL targets in hepatocellular carcinoma eradicate tumor neovascularization, ameliorate the tumor microenvironment, and augment immunotherapy efficacy (97).